Fmoc-(R)-5,5-dimethylthiazolidine-4-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-(R)-5,5-dimethylthiazolidine-4-carboxylic acid
• 英文别名: (4R)-3-(9H-fluoren-9-ylmethoxycarbonyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
• 化学式: C₂₁H₂₁NO₄S
• 分子量: 383.468
• InChiKey: AHWBFHCBDIMJQV-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  92.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Fmoc-(R)-5,5-dimethylthiazolidine-4-carboxylic acid 、 2-甲基烯丙基胺 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors

  摘要：

  The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-1). We recently unveiled a potent hexapeptidic HTLV-1 protease inhibitor, KNI-10166, composed mostly of natural amino acid residues. Herein, we report the derivation of potent tetrapeptidic inhibitor KNI-10516, possessing only non-natural amino acid residues. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.066

文献信息

• Methods for synthesizing α4β7 peptide antagonists
  申请人：Protagonist Therapeutics, Inc.

  公开号：US10407468B2

  公开（公告）日：2019-09-10

  The present invention provides methods of making α4β7 peptide monomer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.

  本发明提供了制造α4β7 肽单体和二聚体拮抗剂的方法。本发明的方法包括固相和溶相方法，以及通过缩合较小的肽片段进行合成的方法。本发明的方法还包括合成包含一个或多个青霉胺残基的肽的方法。
• Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors
  作者：Tooru Kimura、Jeffrey-Tri Nguyen、Hikoichiro Maegawa、Keiji Nishiyama、Yasuhiro Arii、Yasuko Matsui、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2007.04.019

  日期：2007.6

  The human T-cell leukemia virus type 1 (HTLV-I) causes adult T-cell leukemia and several severe chronic diseases. HTLV-I protease (PR) inhibition stops the propagation of the virus. Herein, truncation studies were performed on potent octapeptidie HTLV-I PR inhibitor KNI-10161 to derive small hexapeptide KNI-10127 with some loss in activity. After performing residue-substitution studies on compound KNI-10127, HTLV-I PR inhibitory activity was recovered in inhibitor KNI-10166. (c) 2007 Elsevier Ltd. All rights reserved.
• METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS
  申请人：Protagonist Therapeutics, Inc.

  公开号：US20170327541A1

  公开（公告）日：2017-11-16

  The present invention provides methods of making α4β7 peptide monmer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.
• [EN] METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS<br/>[FR] PROCÉDÉS DE SYNTHÈSE D'ANTAGONISTES DE PEPTIDE Α4Β7
  申请人：PROTAGONIST THERAPEUTICS INC

  公开号：WO2017165676A1

  公开（公告）日：2017-09-28

  The present invention provides methods of making α4β7 peptide monmer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.
• Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors
  作者：Jeffrey-Tri Nguyen、Meihui Zhang、Henri-Obadja Kumada、Ayako Itami、Keiji Nishiyama、Tooru Kimura、Maosheng Cheng、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2007.10.066

  日期：2008.1

  The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-1). We recently unveiled a potent hexapeptidic HTLV-1 protease inhibitor, KNI-10166, composed mostly of natural amino acid residues. Herein, we report the derivation of potent tetrapeptidic inhibitor KNI-10516, possessing only non-natural amino acid residues. (C) 2007 Elsevier Ltd. All rights reserved.